145 related articles for article (PubMed ID: 30538523)
1. Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality.
Youssef AA; Issa HA; Omar MZ; Behiry EG; Elfallah AA; Hasaneen A; Darwish M; Ibrahim DB
Clin Exp Gastroenterol; 2018; 11():431-438. PubMed ID: 30538523
[TBL] [Abstract][Full Text] [Related]
2. Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients.
Alzamzamy A; Elsayed H; Abd Elraouf M; Eltoukhy H; Megahed T; Aboubakr A
World J Gastrointest Oncol; 2021 Jun; 13(6):600-611. PubMed ID: 34163576
[TBL] [Abstract][Full Text] [Related]
3. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma.
Ozaki K; Toshikuni N; George J; Minato T; Matsue Y; Arisawa T; Tsutsumi M
J Cancer; 2014; 5(3):221-30. PubMed ID: 24665346
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma.
Wahb AMSE; El Kassas M; Khamis AK; Elhelbawy M; Elhelbawy N; Habieb MSE
World J Hepatol; 2021 Nov; 13(11):1753-1765. PubMed ID: 34904043
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
6. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Helaly GF; Abou Shamaa LA
Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
[TBL] [Abstract][Full Text] [Related]
7. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
[TBL] [Abstract][Full Text] [Related]
8. Clinical significances and diagnostic utilities of both miR-215 and squamous cell carcinoma antigen-IgM versus alpha-fetoprotein in Egyptian patients with hepatitis C virus-induced hepatocellular carcinoma.
Ali LH; Higazi AM; Moness HM; Farag NM; Saad ZM; Moukareb HA; Soliman W; El Sagheer G; Abd El Hamid SR; Abdl Hamid H
Clin Exp Gastroenterol; 2019; 12():51-66. PubMed ID: 30774409
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients.
Atta MM; Atta HM; Gad MA; Rashed LA; Said EM; Hassanien Sel-S; Kaseb AO
J Hepatocell Carcinoma; 2016; 3():19-24. PubMed ID: 27574588
[TBL] [Abstract][Full Text] [Related]
10. Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.
Yvamoto EY; Ferreira RF; Nogueira V; Pinhe MA; Tenani GD; Andrade JG; Baitello ME; Gregório ML; Fucuta PS; Silva RF; Souza DR; Silva RC
Genet Mol Res; 2015 Dec; 14(4):17453-62. PubMed ID: 26782388
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.
Lacin S; Yalcin S
Technol Cancer Res Treat; 2020; 19():1533033820971677. PubMed ID: 33234055
[TBL] [Abstract][Full Text] [Related]
12. Is serum endocan a sensitive biomarker for early recurrence of hepatocellular carcinoma after radiofrequency ablation?
Omar SA; Attia NM; Sheir MI; Amer AS; El Shabrawy MM; Hasan BB
Eur J Gastroenterol Hepatol; 2021 Jul; 33(7):1015-1022. PubMed ID: 33867440
[TBL] [Abstract][Full Text] [Related]
13. Serum midkine is a more sensitive predictor for hepatocellular carcinoma than Dickkopf-1 and alpha-L-fucosidase in cirrhotic HCV patients.
El-Shayeb AF; El-Habachi NM; Mansour AR; Zaghloul MS
Medicine (Baltimore); 2021 Apr; 100(17):e25112. PubMed ID: 33907088
[TBL] [Abstract][Full Text] [Related]
14. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases.
Ouda SM; Khairy AM; Sorour AE; Mikhail MN
Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
El-Sherif WT; Makhlouf NA; El-Gendi SS; Hassan HI; Herdan OM
Egypt J Immunol; 2012; 19(2):53-65. PubMed ID: 23885407
[TBL] [Abstract][Full Text] [Related]
16. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
17. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma.
Fouad SA; Mohamed NA; Fawzy MW; Moustafa DA
Hepat Mon; 2015 Sep; 15(9):e30753. PubMed ID: 26500684
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3, Vascular Endothelial Growth Factor and Golgi Protein-73 for Differentiation between Liver Cirrhosis and Hepatocellular Carcinoma.
Mamdouh S; Soliman A; Khorshed F; Saber M
Asian Pac J Cancer Prev; 2023 Feb; 24(2):497-507. PubMed ID: 36853298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
